Abstract
A variety of oxazolones (3-18) with structural variation at C-2 and C-4 were synthesized and evaluated as chymotrypsin inhibitors. The synthesized compounds showed varying degree of chymotrypsin inhibitory activity ranging IC50 values from 12.62 ± 1.32 - 126.57 ± 1.06 μM, if compared to standard chymostatin (IC50 = 7.01 ± 0.1 μM). Compounds 3,9,10,13,14, and 15 have IC50 values 17.03 ± 0.78, 69.05 ± 1.48, 12.62 ± 1.32, 17.29 ± 0.93, 126.57 ± 1.06, and 31.55 ± 1.31 μM, respectively. This study reveals that the substitution of functional group (s) at C-2 and C-4 positions plays a vital role in the activity of this series of compounds. The size and electron donating or withdrawing effects of substituents influenced the activity.
Keywords: Synthesis, Oxazolone Derivatives, Chymotrysin inhibition
Letters in Drug Design & Discovery
Title: Synthesis and Chymotrypsin Inhibitory Activity of Substituted Oxazolones
Volume: 5 Issue: 1
Author(s): Khalid Mohammed Khan, Uzma Rasool Mughal, Muhammad Arif Lodhi and Muhammad Iqbal Choudhary
Affiliation:
Keywords: Synthesis, Oxazolone Derivatives, Chymotrysin inhibition
Abstract: A variety of oxazolones (3-18) with structural variation at C-2 and C-4 were synthesized and evaluated as chymotrypsin inhibitors. The synthesized compounds showed varying degree of chymotrypsin inhibitory activity ranging IC50 values from 12.62 ± 1.32 - 126.57 ± 1.06 μM, if compared to standard chymostatin (IC50 = 7.01 ± 0.1 μM). Compounds 3,9,10,13,14, and 15 have IC50 values 17.03 ± 0.78, 69.05 ± 1.48, 12.62 ± 1.32, 17.29 ± 0.93, 126.57 ± 1.06, and 31.55 ± 1.31 μM, respectively. This study reveals that the substitution of functional group (s) at C-2 and C-4 positions plays a vital role in the activity of this series of compounds. The size and electron donating or withdrawing effects of substituents influenced the activity.
Export Options
About this article
Cite this article as:
Khan Mohammed Khalid, Mughal Rasool Uzma, Lodhi Arif Muhammad and Choudhary Iqbal Muhammad, Synthesis and Chymotrypsin Inhibitory Activity of Substituted Oxazolones, Letters in Drug Design & Discovery 2008; 5 (1) . https://dx.doi.org/10.2174/157018008783406624
DOI https://dx.doi.org/10.2174/157018008783406624 |
Print ISSN 1570-1808 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-628X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Noncovalent Binding to DNA: Still a Target in Developing Anticancer Agents
Current Medicinal Chemistry Meet Our Editorial Board Member
Current Medicinal Chemistry Bruton Kinase Inhibitors in Chronic Lymphocytic Leukemia
Anti-Cancer Agents in Medicinal Chemistry Bioactive Proteins and Peptides from Soybeans
Recent Patents on Food, Nutrition & Agriculture Treatment of Chronic Myeloid Leukemia Elderly Patients in the Tyrosine Kinase Inhibitor Era
Current Cancer Drug Targets Overview of Naphthalimide Analogs as Anticancer Agents
Current Medicinal Chemistry Epidemiology and Natural History of Alcoholic Liver Disease
Reviews on Recent Clinical Trials “Endothelial Progenitor Cells” as a Therapeutic Strategy in Cardiovascular Disease
Current Vascular Pharmacology Theranostic Radiopharmaceuticals Targeting Cancer-Associated Fibroblasts
Current Radiopharmaceuticals Interferon alpha for Treatment of Chronic Myeloid Leukemia
Current Drug Targets From Concept to Reality: The Long Road to c-Met and RON Receptor Tyrosine Kinase Inhibitors for the Treatment of Cancer
Anti-Cancer Agents in Medicinal Chemistry Targeting BCR-ABL Oncoprotein for Leukemia Therapy: Current Biotechnology and Future Perspectives
Current Biotechnology Effects of Tyrosine Kinase Inhibitors on Growth and Bone Metabolism in Children with Haematologic Malignancies
Cardiovascular & Hematological Agents in Medicinal Chemistry The Role of Oxidative Stress in Smoking-Related Diseases
Mini-Reviews in Organic Chemistry A 1536-Well Fluorescence Polarization Assay to Screen for Modulators of the MUSASHI Family of RNA-Binding Proteins
Combinatorial Chemistry & High Throughput Screening Kavalactone Pharmacophores for Major Cellular Drug Targets
Mini-Reviews in Medicinal Chemistry Druggability of Mortalin for Cancer and Neuro-Degenerative Disorders
Current Pharmaceutical Design Nanomedicine as a Strategy for Natural Compound Delivery to Prevent and Treat Cancers
Current Pharmaceutical Design Nanomedicine to Overcome Cancer Multidrug Resistance
Current Drug Metabolism Anti-Cancer Therapeutic Approaches Based on Intracellular and Extracellular Heat Shock Proteins
Current Medicinal Chemistry